Open Interest and Volume Dynamics
On 7 Aug 2026, Lupin Ltd. (symbol: LUPIN) recorded an open interest (OI) of 36,692 contracts in its derivatives, up sharply from 29,878 contracts the previous day. This increase of 6,814 contracts, or 22.81%, is a notable jump indicating fresh positions being established or existing ones being rolled over. Concurrently, the volume stood at 49,537 contracts, suggesting active trading interest.
The futures segment alone accounted for a value of approximately ₹50,533.95 lakhs, while options contributed a staggering ₹46,513.97 crores in notional value, culminating in a total derivatives value of ₹58,294.46 lakhs. This substantial derivatives turnover underscores Lupin’s prominence among traders seeking exposure to pharmaceutical sector volatility.
Price Performance and Technical Context
Despite the surge in derivatives activity, Lupin’s underlying share price has shown signs of weakness. The stock closed at ₹2,376, down 1.52% on the day, underperforming its sector by 0.63% and the Sensex by 1.16%. Notably, Lupin has been on a three-day losing streak, shedding 1.71% cumulatively during this period. The price has traded within a narrow ₹10 range, reflecting subdued volatility in the cash market.
Technically, the stock is positioned above its 100-day and 200-day moving averages, which typically indicate medium- to long-term support. However, it remains below its 5-day, 20-day, and 50-day moving averages, signalling short-term bearish momentum. This mixed technical picture may be contributing to cautious investor participation.
Investor Participation and Liquidity
Delivery volumes on 6 Aug fell by 14.69% to 7.58 lakh shares compared to the five-day average, suggesting a decline in committed investor buying. This drop in delivery volume, coupled with the price weakness, points to reduced conviction among long-term holders. Nevertheless, the stock remains sufficiently liquid, with a trade size capacity of ₹6.5 crore based on 2% of the five-day average traded value, facilitating active trading by institutional and retail participants alike.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Market Positioning and Directional Bets
The sharp rise in open interest alongside a moderate increase in volume suggests that market participants are actively repositioning in Lupin’s derivatives. Such a surge often indicates that traders are either building fresh directional bets or hedging existing exposures. Given the stock’s recent price weakness and underperformance relative to the sector, it is plausible that a significant portion of this open interest increase reflects bearish positioning or protective put buying.
However, the fact that Lupin remains above its longer-term moving averages could attract contrarian buyers anticipating a rebound. The derivatives market’s large notional value, especially in options, points to complex strategies involving volatility plays, spreads, and hedges rather than outright directional bets alone.
Mojo Score and Analyst Ratings
Lupin currently holds a Mojo Score of 78.0 with a Mojo Grade of Buy, a slight downgrade from its previous Strong Buy rating as of 3 Aug 2026. This adjustment reflects a tempered outlook amid recent price softness and evolving market dynamics. The mid-cap pharmaceutical stock’s fundamentals remain robust, but near-term technical pressures and investor caution have influenced the rating revision.
Market participants should weigh Lupin’s solid industry positioning and market cap of ₹1,09,448 crore against the current technical signals and derivatives activity to calibrate their exposure accordingly.
Sector and Benchmark Comparison
On the day, Lupin’s 1-day return of -1.06% lagged the Pharmaceuticals & Biotechnology sector’s marginal decline of -0.07% and the Sensex’s fall of -0.36%. This relative underperformance highlights the stock-specific challenges Lupin faces despite the broader sector’s stability. Investors tracking the pharmaceutical space should monitor Lupin’s price action closely, especially given the heightened derivatives interest which may presage increased volatility.
Thinking about Lupin Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Implications for Investors
The surge in Lupin’s open interest signals that traders are positioning for potential near-term volatility. Investors should be cautious and consider the mixed technical signals before increasing exposure. The decline in delivery volumes suggests waning long-term investor conviction, which may weigh on price momentum.
However, Lupin’s strong fundamentals and mid-cap status in a resilient sector provide a solid backdrop for recovery if positive catalysts emerge. Monitoring derivatives activity alongside price and volume trends will be crucial for anticipating directional moves.
In summary, Lupin Ltd. presents a nuanced picture: active derivatives markets and a downgrade in Mojo Grade temper enthusiasm, while underlying sector strength and long-term moving average support offer a foundation for potential upside. Investors should balance these factors carefully in their portfolio decisions.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
